Compare CLRB & JF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLRB | JF |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | China |
| Employees | N/A | 78 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 15.1M |
| IPO Year | 2008 | N/A |
| Metric | CLRB | JF |
|---|---|---|
| Price | $2.96 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 24.1K | 16.9K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.89 |
| 52 Week High | $10.19 | $1.12 |
| Indicator | CLRB | JF |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 55.77 |
| Support Level | $2.76 | $0.90 |
| Resistance Level | $3.44 | $1.02 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 92.98 | 61.59 |
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
J and Friends Holdings Ltd, formerly Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees, as well as by providing financing for these borrowers and earning installment service fees. The company earns wealth management services fees and commissions on financial products. The company generates the majority of its revenue from Wealth management service fees and others.